Grifols, S.A. Stock price

Equities

GRF

ES0171996087

Pharmaceuticals

Real-time Estimate Tradegate 06:42:17 2024-03-28 am EDT 5-day change 1st Jan Change
8.358 EUR +0.75% Intraday chart for Grifols, S.A. -0.90% -46.00%
Sales 2024 * 7.09B 7.65B Sales 2025 * 7.66B 8.26B Capitalization 5.03B 5.43B
Net income 2024 * 482M 520M Net income 2025 * 712M 768M EV / Sales 2024 * 2.01 x
Net Debt 2024 * 9.24B 9.97B Net Debt 2025 * 8.44B 9.11B EV / Sales 2025 * 1.76 x
P/E ratio 2024 *
10.8 x
P/E ratio 2025 *
7.38 x
Employees 23,744
Yield 2024 *
-
Yield 2025 *
3.36%
Free-Float 94.98%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.58%
1 week-1.52%
Current month+9.36%
1 month-28.84%
3 months-41.71%
6 months-31.82%
Current year-46.33%
More quotes
1 week
7.65
Extreme 7.65
9.16
1 month
6.36
Extreme 6.362
11.60
Current year
6.36
Extreme 6.362
15.63
1 year
6.36
Extreme 6.362
15.92
3 years
6.36
Extreme 6.362
25.94
5 years
6.36
Extreme 6.362
34.31
10 years
6.36
Extreme 6.362
34.31
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 06-04-04
Director of Finance/CFO 67 06-12-31
Chief Tech/Sci/R&D Officer - 03-12-31
Members of the board TitleAgeSince
Chief Executive Officer 65 06-04-04
Director/Board Member 68 00-04-12
Director/Board Member 61 01-07-26
More insiders
Date Price Change Volume
24-03-28 8.342 +0.55% 738 542
24-03-27 8.296 -0.10% 1,850,994
24-03-26 8.304 +1.76% 2,132,024
24-03-25 8.16 +3.11% 2,946,832
24-03-22 7.914 -6.03% 11,862,610

Delayed Quote BME, March 28, 2024 at 04:16 am EDT

More quotes
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (77.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (14.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (5.4%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.3%), European Union (11.7%), the United States and Canada (63.6%) and other (19.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
8.296 EUR
Average target price
18.76 EUR
Spread / Average Target
+126.17%
Consensus
  1. Stock
  2. Equities
  3. Stock Grifols, S.A. - BME